Relating to the Texas Pharmaceutical Initiative.

SB 2336 amends Texas law to restructure the governance and reporting requirements for the Texas Pharmaceutical Initiative. It increases the governing board from three to five members appointed by the governor, establishes staggered six-year terms, and requires the board to submit an annual business plan by June 1 each even-numbered year. The plan must detail implementation strategies, including pharmacy benefit management, drug distribution networks, manufacturing of generic drugs and gene therapies, quality control labs, cost savings analysis, and funding needs. This bill directly affects the initiative's board, state agencies administering the program, and future healthcare providers participating in the initiative.